Investigational Drug Information for Elobixibat
✉ Email this page to a colleague
What is the development status for investigational drug Elobixibat?
Elobixibat is an investigational drug.
There have been 12 clinical trials for Elobixibat.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2022.
The most common disease conditions in clinical trials are Constipation, Non-alcoholic Fatty Liver Disease, and Liver Diseases. The leading clinical trial sponsors are Ferring Pharmaceuticals, Yokohama City University, and Albireo.
There are fifty-two US patents protecting this investigational drug and eight hundred and fifty-four international patents.
Summary for Elobixibat
| US Patents | 52 |
| International Patents | 854 |
| US Patent Applications | 131 |
| WIPO Patent Applications | 62 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2022-01-01) |
| Vendors | 29 |
Recent Clinical Trials for Elobixibat
| Title | Sponsor | Phase |
|---|---|---|
| Elobixibat for Chronic Constipation Without Defecation Desire | International University of Health and Welfare | Phase 4 |
| Elobixibat for Chronic Constipation Without Defecation Desire | Yokohama City University | Phase 4 |
| Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation | Synmosa Biopharma Corp. | Phase 3 |
Clinical Trial Summary for Elobixibat
Top disease conditions for Elobixibat
Top clinical trial sponsors for Elobixibat
US Patents for Elobixibat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Elobixibat | ⤷ Sign Up | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | ⤷ Sign Up |
| Elobixibat | ⤷ Sign Up | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | ⤷ Sign Up |
| Elobixibat | ⤷ Sign Up | IBAT inhibitors for the treatment of liver diseases | Albireo AB (N/A) | ⤷ Sign Up |
| Elobixibat | ⤷ Sign Up | [5,6]--fused bicyclic antidiabetic compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Elobixibat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Elobixibat | Australia | AU2011326871 | 2030-11-08 | ⤷ Sign Up |
| Elobixibat | Brazil | BR112013010157 | 2030-11-08 | ⤷ Sign Up |
| Elobixibat | Canada | CA2815749 | 2030-11-08 | ⤷ Sign Up |
| Elobixibat | China | CN103260625 | 2030-11-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
